SR One led a round disclosed by the genetic medicine developer, a spinout of University of Wisconsin-Madison, as it emerged from stealth.

UC Berkeley's Nurix Therapeutics will use the capital to prepare two protein modulation-based immuno-oncology drugs for the clinic.

Celgene-backed Nurix Therapeutics will use the capital to advance two protein modulation-based immuno-oncology drug candidates toward clinical trials.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Susquehanna International Group co-led a series C round for insurance technology developer InsGeek, whose shareholders already include Legend Holdings and Fosun.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Circle Pharma, a spinout of UCSF and UC Santa Cruz, has collected series B funding from investors including another UC campus, Berkeley.

Eli Lilly took part in an $80.3m round that pushed chronic illness drug developer Sigilon Therapeutics' overall funding to nearly $200m.

Strategic partner Lyell Immunopharma led a $45m round for Eureka Therapeutics, which will use the money to advance a pipeline that includes a treatment for liver cancer.